These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 22799018)

  • 1. [Atrial fibrillation: where is the border between pure antiarrhythmic and non-antiarrhythmic medicines?].
    Moiseev SV
    Kardiologiia; 2012; 52(2):85-90. PubMed ID: 22799018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Status of Antiarrhythmic Drug Development for Atrial Fibrillation: New Drugs and New Molecular Mechanisms.
    Hanley CM; Robinson VM; Kowey PR
    Circ Arrhythm Electrophysiol; 2016 Mar; 9(3):e002479. PubMed ID: 26936819
    [No Abstract]   [Full Text] [Related]  

  • 3. [New class III antiarrhythmic drugs for treatment of atrial fibrillation].
    Maĭkov EB
    Kardiologiia; 2012; 52(11):56-65. PubMed ID: 23237397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comprehensive insight of novel antioxidant therapies for atrial fibrillation management.
    Orenes-Piñero E; Valdés M; Lip GY; Marín F
    Drug Metab Rev; 2015 Aug; 47(3):388-400. PubMed ID: 27412960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rhythm control of atrial fibrillation in heart failure.
    Heijman J; Voigt N; Abu-Taha IH; Dobrev D
    Heart Fail Clin; 2013 Oct; 9(4):407-15, vii-viii. PubMed ID: 24054474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Electropharmacological effects of antiarrhythmic drugs on atrial fibrillation termination. Part II: New insights into the electrophysiological mechanisms of atrial fibrillation termination.
    Calò L; Sciarra L; Lamberti F; Loricchio ML; Castro A; Bianconi L; Pandozi C; Gaita F; Santini M
    Ital Heart J; 2003 Jul; 4(7):442-7. PubMed ID: 14558294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rate vs rhythm control in atrial fibrillation: can observational data trump randomized trial results?
    Dewland TA; Marcus GM
    Arch Intern Med; 2012 Jul; 172(13):983-4. PubMed ID: 22665022
    [No Abstract]   [Full Text] [Related]  

  • 8. Omega-3 fatty acid: a role in the management of cardiac arrhythmias?
    Cheng JW; Santoni F
    J Altern Complement Med; 2008 Oct; 14(8):965-74. PubMed ID: 18928392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel K+ Channel Targets in Atrial Fibrillation Drug Development--Where Are We?
    El-Haou S; Ford JW; Milnes JT
    J Cardiovasc Pharmacol; 2015 Nov; 66(5):412-31. PubMed ID: 25978691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New drugs for atrial fibrillation.
    Hammwöhner M; Smid J; Lendeckel U; Goette A
    J Interv Card Electrophysiol; 2008 Oct; 23(1):15-21. PubMed ID: 18535890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is there a role for digoxin in atrial fibrillation without heart failure?
    Master J; Schweitzer P
    Cardiol J; 2009; 16(5):483-6. PubMed ID: 19753533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiarrhythmic therapy in atrial fibrillation: indications, guidelines, and safety.
    Barekatain A; Razavi M
    Tex Heart Inst J; 2012; 39(4):532-4. PubMed ID: 22949771
    [No Abstract]   [Full Text] [Related]  

  • 13. Selection of drugs in pursuit of a rhythm control strategy.
    Kowey PR; Stoenescu ML
    Prog Cardiovasc Dis; 2005; 48(2):139-45. PubMed ID: 16253653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rate control versus rhythm control in atrial fibrillation: lessons learned from clinical trials of atrial fibrillation.
    Waldo AL
    Prog Cardiovasc Dis; 2015; 58(2):168-76. PubMed ID: 26260611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Innovative Therapeutics for Atrial Fibrillation: Imminent Breakthroughs or Much Ado About Nothing?
    Nattel S; Dobrev D
    J Cardiovasc Pharmacol; 2015 Nov; 66(5):409-11. PubMed ID: 26371951
    [No Abstract]   [Full Text] [Related]  

  • 16. [Pharmacologic maintenance of sinusal rhythm and/or control of the ventricular response in patients with atrial fibrillation or flutter].
    López Gil M; Arribas F; Hernández Afonso J; Angel Santos M; García-Cosío F
    Rev Esp Cardiol; 1996; 49 Suppl 2():32-41. PubMed ID: 8755694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is rate control better than rhythm control for atrial fibrillation in older high-risk patients?
    Saseen JJ
    J Fam Pract; 2003 Mar; 52(3):192, 194. PubMed ID: 12620170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atrial Fibrillation and Congestive Heart Failure: should we aim to control the heart's rate or its rhythm?
    Capucci A
    Nat Clin Pract Cardiovasc Med; 2009 Jan; 6(1):6-7. PubMed ID: 18957958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Electropharmacological effects of antiarrhythmic drugs on atrial fibrillation termination. Part I: Molecular and ionic fundamentals of antiarrhythmic drug actions.
    Calò L; Sciarra L; Lamberti F; Loricchio ML; Castro A; Bianconi L; Pandozi C; Gaita F; Santini M
    Ital Heart J; 2003 Jul; 4(7):430-41. PubMed ID: 14558293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term antiarrhythmic drug treatment after atrial fibrillation ablation: does a too obstinate rhythm control strategy bring serious risk of proarrhythmia to ablated patients?
    De Vecchis R
    Eur Heart J Cardiovasc Pharmacother; 2019 Apr; 5(2):117-118. PubMed ID: 30398614
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.